
7 Literatur

- ¹ Kadan-Lottick NS, Kawashima T et al. : The risk of cancer in twins: A report from the childhood cancer survivor study. *Ped Blood Cancer* (2006) 46:476-81
- ² Greaves M: Molecular genetics, Natural history and the Demise of childhood leukemia. *Eur J Cancer* (1999) 35:173-155
- ³ Wiemels JL, Cazzaniga G et al. : Prenatal origin of acute lymphoblastic leukemia in children. *Lancet* (1999) 354:1499-503
- ⁴ Amare P, Gladstone B et al. : Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult acute lymphoblastic leukemia: Experience from India. *Cancer Genet Cytogenet* (1999)110:44-53
- ⁵ Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. *Blood* (1997) 90:4243-4251
- ⁶ Harrison CJ: The genetics of childhood acute lymphoblastic leukaemia. *Baillière's Clin Haem* (2000) 13:427-439
- ⁷ Rubnitz JE, Look AT: Molecular genetics of childhood leukemias. *J Pediatr Hematol Oncol* (1998) 20:1-11
- ⁸ Ma SK, Wan TSK et al. : Cytogenetics and molecular genetics of childhood leukemia. *Hematol Oncol* (1999) 17:91-105
- ⁹ Thandla S, Aplan PD: Molecular biology of acute lymphoblastic leukemia. *Semin Oncol* (1997) 24:45-56
- ¹⁰ Rowley JD: The critical role of chromosome translocations in human leukemias. *Annu Rev Genet* (1998) 32:495-519
- ¹¹ Camitta BM, Pullen J et al. : Biology and treatment of acute lymphoblastic leukemia in children. *Semin Oncol* (1997) 24:83-91
- ¹² Smith M, Arthur D et al. : Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol* (1996) 14:18-24
- ¹³ Wood AJJ: Acute lymphoblastic leukemia. *N Engl J Med* (1998) 339:605-615
- ¹⁴ Pui CH, Evans WE: Acute lymphoblastic leukemia. *N Engl J Med* (1998) 339:605-615
- ¹⁵ Pallisgaard N, Clausen N et al. : Rapid and sensitive minimal residual disease detection in acute lymphoblastic leukemia by quantitative real-time RT-PCR exemplified by t(12;21) *TEL-AML1* fusion transcript. *Genes Chromosomes Cancer* (1999) 26:355-365
- ¹⁶ Potter MN, Steward CG et al. : The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. *Br J Haematol* (1993) 83(3):412-418

-
- ¹⁷ Brisco MJ, Condon J et al. : Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. *Lancet* (1994) 343:196-200
- ¹⁸ Cavé H, Van der Werff ten Bosch J et al. : Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. *N Engl J Med* (1998) 339:591-598
- ¹⁹ van Dongen JJM, Seriu T et al. : Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. *Lancet* (1998) 352:1731-1738
- ²⁰ Eckert C, Biondi A et al. : Prognostic value of minimal residual disease in relapsed childhood lymphoblastic leukaemia. *Lancet* (2001) 358:1239-1241
- ²¹ Knechtli CJ, Goulden NJ et al. : Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. *Blood* (1998) 92:4072-4097
- ²² Bader P, Hancock J et al: Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post transplant outcome in children with ALL. *Leukemia* (2002)16:1668-1672
- ²³ Wang LC, Swat W et al. : The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. *Genes Dev* (1998) 12:2392-2402
- ²⁴ Baens M, Peeters P et al. : Genomic organization of TEL: the human ETS-variant gene 6. *Genome Res* (1996) 6:404-413
- ²⁵ Jousset C, Carron C et al. : A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR β oncoprotein. *EMBO J* (1997) 16:69-82
- ²⁶ Agape P, Gerard B et al. : Analysis of ETV6 and ETV6-*AML1* proteins in acute lymphoblastic leukaemia. *Br J Haematol* (1997) 98:234-239
- ²⁷ Poirel H, Lacronique V et al. : Analysis of TEL proteins in human leukemias. *Oncogene* (1998) 16:2895-2903
- ²⁸ Golub TR, Barker GF et al. : Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell* (1994) 77:307-316
- ²⁹ Peeters P, Raynaud SD et al. : Fusion of TEL, the ETS-Variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. *Blood* (1997) 90:2535-2540

- ³⁰ Buijs A, Sherr S et al. : Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like *TEL* gene on 12p13 to the *MN1* gene on 22q11. *Oncogene* (1995) 10:1511-1519
- ³¹ Stegmaier K, Pendse S et al. : Frequent loss of heterozygosity at the *TEL* gene locus in acute lymphoblastic leukemia of childhood. *Blood* (1995) 86:38-44
- ³² Raynaud S, Cave H et al. : The 12;21 translocation involving *TEL* and deletion of the other *TEL* allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. *Blood* (1996) 87:2891-2899
- ³³ Ghozi MC, Bernstein Y et al. : Expression of the human myeloid leukemia gene *AML1* is regulated by two promotor regions. *Proc Natl Acad Sci USA* (1996) 93:1935-1940
- ³⁴ Miyoshi H, Ohira M et al. : Alternative splicing and genomic structure of the *AML1* gene involved in acute myeloid leukemia. *Nucleic Acids Res* (1995) 23:2762-2769
- ³⁵ Levanon D, Negreanu V et al. : *AML1*, *AML2*, and *AML3*, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. *Genomics* (1994) 23:425-432
- ³⁶ Miyoshi H, Shimizu K et al. : t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, *AML1*. *Proc Natl Acad Sci USA* (1991) 88:10431-10434
- ³⁷ Wiemels JL, Greaves M : Structure and possible mechanisms of *TEL-AML1* gene fusions in childhood acute lymphoblastic leukemia. *Cancer Res* (1999) 59:4075-4082
- ³⁸ Wiemels JL, Alexander FE et al. : Microclustering of *TEL-AML1* translocation breakpoints in childhood acute lymphoblastic leukemia. *Genes Chromosomes Cancer* (2000) 29:219-228
- ³⁹ Romana SP, Mauchauffé M et al. : The t(12;21) of acute lymphoblastic leukemia results in a *TEL-AML1* gene fusion. *Blood* (1995) 85:3662-3670
- ⁴⁰ Bernard OA, Romana SP et al. : Molecular Cytogenetics of t(12;21)(p13;q22). *Leuk Lymphoma* (1996) 23:459-465
- ⁴¹ McLean TW, Ringold S et al. : *TEL/AML1* dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. *Blood* (1996) 88:4252-4258
- ⁴² Seeger K, von Stackelberg A et al. : Relapse of *TEL-AML1* positive lymphoblastic leukemia in childhood: A matched-pair analysis. *J Clin Oncol* (2001) 19:3188-3193

-
- ⁴³ Harbott J, Viehmann S et al. : Incidence of *TEL/AML1* fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. *Blood* (1997) 90:4933-4937
- ⁴⁴ Loh ML, Rubnitz JE: *TEL/AML1*-positive pediatric leukemia: prognostic significance and therapeutic approaches. *Curr Opin Hematol* (2002) 9:345-352
- ⁴⁵ Loncarevic IF, Roitzheim B et al. : Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with *TEL/AML1* gene fusion. *Genes Chromosomes Cancer* (1999) 24:272-277
- ⁴⁶ Rubnitz JE, Downing JR et al. : *TEL* gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance. *J Clin Oncol* (1997) 15:1150-1157
- ⁴⁷ Seeger K, Adams HP et al. : *TEL-AML1* fusion transcript in relapsed childhood acute lymphoblastic leukemia. *Blood* (1998) 91:1716-1722
- ⁴⁸ Rubnitz JE, Behm FG et al. : Low frequency of *TEL-AML1* in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. *Leukemia* (1999)13:19-21
- ⁴⁹ Loh ML, Silverman LB et al. : Incidence of *TEL/AML1* fusion in children with relapsed acute lymphoblastic leukemia. *Blood* (1998) 92:4792-4797
- ⁵⁰ Ramakers-van Woerden NL, Pieters R et al.: *TEL/AML1* gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. *Blood* (2000) 96:1094-1099
- ⁵¹ Ford AM, Fasching R et al.: Origins of „late“ relapse in childhood acute lymphoblastic leukemia with *TEL-AML1* fusion genes. *Blood* (2001) 98:558-564
- ⁵² Invitrogen BV, Groningen, Netherlands: Product Specification for pCR® 2.1-TOPO, 3908 nucleotides.
- ⁵³ Satake N, Kobayashi H et al. : Minimal residual disease with *TEL-AML1* fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). *Br J Haematol* (1997) 97:607-611
- ⁵⁴ Shurtleff SA, Buijs A et al.: *TEL/AML1* fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. *Leukemia* (1995) 9:1985-1989
- ⁵⁵ Rubnitz JE, Pui C-H et al. : The role of *TEL* fusion genes in pediatric leukemias. *Leukemia* (1999) 13:6-13

-
- ⁵⁶ Kwiatkowski BA, Bastian LS et al. : The *ets* family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity. *J Biol Chem* (1998) 273:17525-17530
- ⁵⁷ Kwiatkowski BA, Zielinska-Kwiatkowska AG et al. : The ETS family member Tel antagonizes the Fli-1 Phenotype in hematopoietic cells. *Blood Cells Mol Dis* (2000) 26:84-90
- ⁵⁸ Chakrabarti SR, Sood R et al. : Posttranslational modification of TEL and TEL/*AML1* by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. *PNAS* (2000) 97:13281-13285
- ⁵⁹ Lopez RG, Carron C et al. : TEL is a sequence-specific transcriptional repressor. *J Biol Chem* (1999) 274:30123-30138
- ⁶⁰ Wang L, Hiebert SW: TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. *Oncogene* (2001) 20:3716-3725
- ⁶¹ Hiebert SW, Sun W et al. : The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. *Mol Cell Biol* (1996) 16:1349-1355
- ⁶² Tanaka T, Tanaka K et al. : An acute myeloid leukemia gene, *AML1*, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative *spliced* forms. *EMBO J* (1995) 14:341-350
- ⁶³ Okuda T, van Deursen J et al. : *AML1*, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* (1996) 84:321-330
- ⁶⁴ Okuda T, Cai Z et al. : Expression of a knocked-in *AML1*-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. *Blood* (1998) 91:3134-3143
- ⁶⁵ Okada H, Watanabe T et al. : *AML1*(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. *Oncogene* (1998) 17:2287-2293
- ⁶⁶ Wang Q, Stacy T et al. : Disruption of the *Cbfa2* gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc Natl Acad Sci USA* (1996) 93:3444-3449
- ⁶⁷ Downing JR, Higuchi M et al. : Alteration of the *AML1* transcription factor in human leukemia. *Cell & Develop Biol* (2000) 11:347-360
- ⁶⁸ Kim D, Moldwin RL et al. : *TEL-AML1* translocation with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. *Blood* (1996) 88:785-794

-
- ⁶⁹ Uchida H, Downing JR et al. : Three distinct domains in *TEL-AML1* are required for transcriptional repression of the IL-3 promoter. *Oncogene* (1999) 18:1015-1022
- ⁷⁰ Fears S, Gavin M et al. : Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. *Proc Natl Acad Sci USA* (1997) 94:1949-1954
- ⁷¹ Bernardin F, Yang Y et al. : *TEL-AML1*, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. *Cancer Res* (2002) 62:3904-3908
- ⁷² Borkhardt A, Cazzaniga G et al. : Incidence and clinical relevance of *TEL/AML1* fusion genes in children with acute lymphoblastic leukemia enrolled in the german and italian multicenter therapy trials. *Blood* (1997) 90:571-577
- ⁷³ Heerema NA, Sork L et al. : *TEL-AML1* expression in childhood acute lymphoblastic leukemia (ALL) is associated with rapid early response (RER) to induction chemotherapy. *Blood* (1999) 94:502a
- ⁷⁴ Spathas DH, Stewart J et al. : Detection of t(12;21) in childhood acute lymphoblastic leukemia by fluorescence in situ hybridization. *Cancer Genet Cytogenet* (1999) 110:7-13
- ⁷⁵ Farahat N, Morilla A et al. : Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. *Br J Haematol* (1998) 101:158-164
- ⁷⁶ Ciudad J, San Miguel JF et al. : Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. *J Clin Oncol* (1998) 16:3774-3781
- ⁷⁷ Coustan-Smith E, Behm FG et al.: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. *Lancet* (1998) 351:550-554
- ⁷⁸ Coustan-Smith E, Sancho J et al. : Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. *Blood* (2000) 96:2691-2696
- ⁷⁹ Dworzak MN, Froschl G et al. : Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. *Blood* (2002) 99:1523-1533
- ⁸⁰ Steenbergen AJ, Verhagen OJHM et al. : Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. *Leukemia* (1995) 9:1726-1734

-
- ⁸¹ Ginzinger DG: Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. *Exp Hematol* (2000) 30:503-512
- ⁸² Pongers-Willemse MJ, Verhagen OJ et al. : Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. *Leukemia* (1998) 12:2006-2014
- ⁸³ Drunat S, Olivi M et al. : Quantification of *TEL-AML1* transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. *Br J Haematol* (2001) 114:281-289
- ⁸⁴ Nakao M, Janssen JWG et al. : Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-Cell receptor loci by LightCycler technology. *Cancer Res* (2000) 60:3281-3289
- ⁸⁵ Eckert C, Landt O et al. : Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. *Leukemia* (2000) 14:316-323
- ⁸⁶ Kreuzer KA, Lass U et al. : LightCycler Technology for the quantitation of bcr/abl fusion transcripts. *Cancer Res* (1999) 59:3171-3174
- ⁸⁷ Bolufer P, Barragan E et al. : Rapid quantitative detection of *TEL-AML1* fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. *Haematologica* (2002) 87:23-32
- ⁸⁸ Van Dongen JJM, Macintyre EA et al. : Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. *Leukemia* (1999)13:1901-1928
- ⁸⁹ Goulden NJ, Knechtli CJC et al. : Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. *Br J Haematol* (1998) 100:235-244
- ⁹⁰ Beishuizen A, Verhoeven MJ et al. : Analysis of Tg and T-Cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis. *Blood* (1994) 83:2238-2247
- ⁹¹ Szczepanski T, Willemse MJ et al. : Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides im-

proved strategies for selection of stable PCR targets for monitoring of minimal residual disease. *Blood* (2002) 99:2315-2323

⁹² De Haas V, Breunis WB et al. : The *TEL-AML1* real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. *Br J Haematol* (2002) 116:87-93

⁹³ Kreuzer KA, Lass U et al. : Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of β -Actin transcripts as quantitative reference. *Clin Chem* (1999) 45:297-300

⁹⁴ Seeger K, Kreuzer KA et al. : Molecular quantification of response to therapy and remission status in *TEL-AML1* positive childhood ALL by real-time reverse transcription polymerase chain reaction. *Cancer Res* (2001) 61:2517-2522

⁹⁵ Ballerini P, Landmann Parker J et al. : Quantitative analysis of *TEL/AML1* fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia. *Leukemia* (2000) 14:1526-1531

⁹⁶ Henze G, Fengler R et al. : Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group. *Blood* (1991) 78:1166-1172

⁹⁷ Zuna J, Hrusák et al. : Significantly lower relapse rate for *TEL/AML1*-positive ALL. *Leukemia* (1999) 13: 1633-1638